Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
Bill Ackman backed Mark Cuban's drug pricing model. Here's which healthcare stocks could benefit—and which face pressure.
Stocks · News reference
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today
The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.
Can Cigna's Smart Coverage Help Close Health-Cost Gaps?
Cigna Healthcare is introducing Smart Coverage, a new benefit option that automatically links medical claims with supplemental benefits to provide eligible members up to $7,000 for covered health events. The program launches January 1, 2027, for mid-sized employers and addresses a significant affordability gap, with nearly 60% of Americans unprepared for health costs. The initiative is designed to increase enrollment in high-deductible plans and boost supplemental product participation.
UBS Maintains Buy on CVS Health, Lowers Price Target to $118
Watching Freenome; Traders Circulate Unconfirmed Analyst Comments Suggesting Carelon Healthcare Services (ELV) Just Updated Clinical Guideline Reimbursements To Include Freenome’s SimpleScreen
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026
Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.